JD Health Earnings Call Highlights Profits, AI Push

JD Health International, Inc. ((HK:6618)) has held its Q4 earnings call. Read on for the main highlights of the call.

JD Health International, Inc. struck an upbeat tone on its latest earnings call, underscoring another year of robust expansion and improving profitability. Management highlighted double‑digit revenue gains, faster non‑IFRS profit growth, margin expansion and strong cash generation, while framing higher costs and AI monetization challenges as manageable execution issues rather than structural threats.

Accelerating Top-Line Momentum

JD Health reported full‑year 2025 revenue of RMB 73.4 billion, up 26.3% year on year, with fourth‑quarter revenue climbing 27.4% to RMB 21.0 billion. The company has now delivered more than 20% revenue growth for four consecutive quarters, signalling durable demand across its online healthcare and pharmacy ecosystem.

Profits Rise Faster Than Sales

Non‑IFRS profit jumped 36.3% to RMB 6.5 billion for 2025, pushing the non‑IFRS margin to 8.9%, the highest level since the company’s IPO. In the fourth quarter, non‑IFRS profit reached RMB 1.1 billion, up 13.5% year on year, though the quarterly margin of 5% shows some seasonal and investment‑related pressure.

Gross Margin Boost From Scale and Supply Chain

The company’s 2025 gross margin improved to 24.8%, expanding by 1.9 percentage points versus the prior year. Management attributed this to the growing weight of its direct‑sales model and efficiency gains from its “super” pharmaceutical supply chain, which is increasingly central to JD Health’s economics.

Direct Sales Engine and Rising Service Mix

Direct sales remained the core revenue driver, generating RMB 60.9 billion in 2025, up 24.8% and accounting for 82.9% of total revenue. Service revenue, though smaller at RMB 12.6 billion, grew faster at 34.1% and rose to 17.1% of total revenue, indicating gradual diversification toward higher‑margin service businesses.

Expanding User Base and AI-Driven Engagement

Annual active user accounts reached about 220 million over the past 12 months, a net increase of 34 million from the prior year‑end. The AI health agent “Dr. Da Wei” completed hundreds of millions of interactions with a reported 98% satisfaction rate, underscoring deep user engagement and JD Health’s technology reach.

New Product Pipeline Delivers Early Wins

JD Health dramatically stepped up its product launch cadence, introducing over 100 new drugs in 2025 compared with about 30 in 2024. The sleep‑medicine launch DAYVIGO recorded more than 20,000 orders in its first month, while a premium fish oil product generated roughly 15 billion online impressions on its launch day, showcasing marketing and traffic strength.

Broader Service Footprint and Channel Reach

Online medical insurance payment coverage was extended to 29 key cities, deepening JD Health’s integration with China’s healthcare reimbursement system. The company also grew its offline presence to more than 300 self‑operated pharmacies and saw at‑home rapid testing orders surge 81.9% year on year, supporting its on‑demand healthcare strategy.

AI and Clinical Solutions Gain Traction

On the clinical front, the JOY DOC platform has served over 5 million patients at partner hospitals, highlighting institutional adoption. JD Health rolled out multiple AI offerings, including AI Jingyi, JOY DOC enhancements, AI doctor “digital twins” and device link‑ups such as a JD‑branded continuous glucose monitor developed with Yuwell.

Strong Cash Generation and Financial Position

Operating activities produced RMB 10.2 billion in cash flow during 2025, underscoring the business’s cash‑generating capacity. Finance income totalled RMB 1.5 billion, and management pointed to a net increase of roughly RMB 10.1 billion in cash, cash equivalents and related assets, indicating ample liquidity despite some reporting clarifications.

Cost Pressures Accompany Scale

Selling and marketing expenses rose about 26.9% year on year, roughly in line with revenue growth, leaving the S&M ratio stable at 5.2%. Fulfillment costs edged higher, with the fulfillment expense ratio up 0.2 percentage points to 10.4%, signaling that logistics and service expansion are adding some strain even as efficiency efforts continue.

AI Monetization Still a Work in Progress

Management emphasized that its AI assets, including Dr. Da Wei and broader AI tools, are driving engagement and service quality but are not yet fully monetized. The path to turning these highly utilized platforms into meaningful, direct revenue streams—especially for business‑facing doctor tools—remains in development and could influence future earnings leverage.

Revenue Concentration and Offline Trade-Offs

With direct sales making up 82.9% of revenue, JD Health faces concentration risk should supplier or category dynamics shift in that channel. At the same time, management views offline pharmacies as strategically important but lower‑margin, opting for a measured rollout of its roughly 300 self‑operated locations rather than aggressive expansion that could dilute profitability.

Reporting Complexity and Competitive Landscape

The call featured corrected figures for certain balance sheet items and “other income and gains,” which may create short‑term uncertainty around exact liquidity measures even if the overall picture remains solid. Management also flagged intensifying competition from both online and offline players, suggesting that defending market share may require sustained investment and could pressure some categories.

Guidance Signals Confident but Disciplined Growth

Looking ahead, JD Health signalled plans to sustain high‑quality growth by leaning into its pharmaceutical supply chain, direct‑sales platform and AI‑enabled services while carefully integrating online and offline operations. Management aims to build on 2025’s revenue of RMB 73.4 billion and non‑IFRS profit of RMB 6.5 billion, viewing AI, new drug launches, on‑demand retail and insurance‑linked services as multi‑year growth engines, with a clear focus on sustainable margins and user expansion.

JD Health’s latest earnings call painted a picture of a company balancing strong growth, improving profitability and heavy investment in technology and channels. Investors will need to weigh execution risks around AI monetization, cost discipline and competition, but the underlying momentum in revenue, margins, users and cash flow positions the company as a notable player in China’s evolving healthcare market.